Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

IMMY20022/CAEL101-301/Frank Passero

Basic Study Information

Purpose:
AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine if CAEL-101 improves the overall survival in Patients with cardiac AL Amyloidosis.

Location: University of Rochester- Wilmot Cancer Center

Lead Researcher (Principal Investigator)

Lead Researcher:  Frank Passero

Study Contact Information

Study Coordinator: Tina Bowdish
Phone: +1 585-275-9475
Email: tina_bowdish@urmc.rochester.edu

Additional Study Details

Return to Search